IL17A and non-small cell lung carcinoma: Th1/Th2 cell and Th17/Treg cell ratios are unbalanced in NSCLC patients with CIP undergoing anti-PD-1/PD-L1 immunotherapy, leading to the increased secretion of IL-17A and IL-35 in BALF and serum (54).